Skip to Main Content

We have a new app!

Take the Access library with you wherever you go—easy access to books, videos, images, podcasts, personalized features, and more.

Download the Access App here: iOS and Android

CHAPTER 87: ANTIARRHYTHMIC DRUGS

Joshua M. Arkin; Colleen Hanley; Gan-Xin Yan; Peter R. Kowey

PRINCIPLES OF ANTIARRHYTHMIC DRUG THERAPY

The treatment of patients with tachyarrhythmias has evolved dramatically over the past several decades. However, even with advances in catheter ablation and implantable cardioverter-defibrillators, antiarrhythmic drug therapy remains a cornerstone in the treatment of nearly every form of cardiac arrhythmia. An in-depth knowledge of the pharmacology of antiarrhythmic drugs, including their pharmacokinetics and pharmacodynamics, is essential to their successful and safe implementation (Table 87–1).

TABLE 87–1.Vaughan-Williams Classification of Antiarrhythmic Drugs
View Table||Download (.pdf)
TABLE 87–1. Vaughan-Williams Classification of Antiarrhythmic Drugs
Action Example Drugs
I Sodium channel blockade
Ia Block sodium channel in open state with an intermediate recovery from block; also, inhibit IKr at relatively lower concentrations; moderate phase 0 depression and conduction slowing, prolonging of action potential duration. Quinidine, procainamide, disopyramide
Ib Block sodium channel in inactivated state with a fast time constant of recovery from block; minimal effect on phase 0 upstroke; no change or slight shortening of action potential duration. Lidocaine, mexiletine
Ic Block sodium channel in open state with slow recovery from block; marked phase 0 depression and conduction slowing; small or no effect on repolarization. Flecainide, propafenone
II β-Adrenergic receptor blockade. Propranolol, metoprolol, atenolol, esmolol, acebutolol, pindolol, nadolol, carvedilol, labetalol, and bisoprolol
III Potassium channel blockade and/or inward current enhancer. d,l-Sotalol, dofetilide, amiodarone, bretylium, ibutilide, dronedarone
IV Calcium channel blockade. Verapamil, diltiazem

MECHANISMS UNDERLYING ANTIARRHYTHMIC AND PROARRHYTHMIC EFFECTS

The development of cardiac arrhythmias and drug-induced proarrhythmias can be a result of abnormal impulse formation (ie, enhanced automaticity and triggered activities) and/or reentry. This section provides a brief overview of ionic and cellular mechanisms underlying the antiarrhythmic and proarrhythmic effects of the drugs.

Ion Channel Physiology

Antiarrhythmic drugs exert their effects on cardiac electrical impulse formation and propagation via their interaction with ionic channels or with membrane receptors and cellular pumps that subsequently influence ionic currents across the cell membrane. Cardiac ionic currents commonly targeted by antiarrhythmic drugs include inward sodium current (INa), L-type calcium current (ICa,L), and delayed rectifier outward potassium current (IK), which consists of two components—a rapidly activating component (IKr) and a slowly activating component (IKs). Although transient outward potassium current (Ito) is not commonly influenced by currently available antiarrhythmic drugs, it has been shown to contribute importantly to the genesis of polymorphic ventricular tachycardia and ventricular fibrillation.1 Therefore, antiarrhythmic drugs with selective Ito blockade will be favored in future drug development.

Antiarrhythmic drugs that block the sodium channel appear to bind selectively to the channel during designated states and dissociate from the channel during the other states. Therefore, a sodium channel blocker will block the sodium channel differently depending on pathologic conditions. The maximal velocity of ...

Pop-up div Successfully Displayed

This div only appears when the trigger link is hovered over. Otherwise it is hidden from view.

This site uses cookies to provide, maintain and improve your experience. MH Privacy Center Close